DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of 177Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma

Cameron N. Johnstone; Laura D. Osellame; Zhipeng Cao; Alexander F. McDonald; Angela Rigopoulos; Ingrid J.G. Burvenich; Christian W. Wichmann; Nancy Guo; Alesia N. Ivashkevich; Michael P. Wheatcroft; Edwin B. Yan; Astrid Zimmermann; Frank T. Zenke; Christian Sirrenberg; Fiona E. Scott; Andrew M. Scott

doi:10.2967/jnumed.124.268695

Research ArticleBasic Science Investigation

DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of ¹⁷⁷Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma

Cameron N. Johnstone, Laura D. Osellame, Zhipeng Cao, Alexander F. McDonald, Angela Rigopoulos, Ingrid J.G. Burvenich, Christian W. Wichmann, Nancy Guo, Alesia N. Ivashkevich, Michael P. Wheatcroft, Edwin B. Yan, Astrid Zimmermann, Frank T. Zenke, Christian Sirrenberg, Fiona E. Scott and Andrew M. Scott

Journal of Nuclear Medicine March 2025, 66 (3) 385-390; DOI: https://doi.org/10.2967/jnumed.124.268695

Cameron N. Johnstone

1Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia;

2School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia;

3Department of Clinical Pathology, University of Melbourne, Parkville, Victoria, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Laura D. Osellame

1Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia;

2School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Zhipeng Cao

1Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia;

2School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia;

4Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Alexander F. McDonald

1Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia;

2School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia;

4Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Angela Rigopoulos

1Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia;

2School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ingrid J.G. Burvenich

1Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia;

2School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Christian W. Wichmann

1Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia;

2School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia;

4Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Nancy Guo

1Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Alesia N. Ivashkevich

5Telix Pharmaceuticals, North Melbourne, Victoria, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michael P. Wheatcroft

5Telix Pharmaceuticals, North Melbourne, Victoria, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Edwin B. Yan

5Telix Pharmaceuticals, North Melbourne, Victoria, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Astrid Zimmermann

6Merck KGaA, Darmstadt, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Frank T. Zenke

7EMD Serono, Billerica, Massachusetts; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Christian Sirrenberg

6Merck KGaA, Darmstadt, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Fiona E. Scott

1Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia;

2School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Andrew M. Scott

1Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia;

2School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia;

4Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia;

8Department of Medicine, University of Melbourne, Parkville, Victoria, Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Individuals

Non-Member Login

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 66, Issue 3

March 1, 2025

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of 177Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of ¹⁷⁷Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma

Journal of Nuclear Medicine Mar 2025, 66 (3) 385-390; DOI: 10.2967/jnumed.124.268695

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of ¹⁷⁷Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma

Journal of Nuclear Medicine Mar 2025, 66 (3) 385-390; DOI: 10.2967/jnumed.124.268695

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

No citing articles found.

Google Scholar

Keywords

girentuximab
rosopatamab
177Lu
peposertib
DNA damage response

Main menu

User menu

Search

DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of ¹⁷⁷Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma

Individuals

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords